MARPAM PHARMA, LLC

Biotech · Private

Autologous CAR-T cell therapy engineered with CXCR5 homing receptor to target HIV-infected cells in lymphoid B cell follicles

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Total capital: $5.4M

Federal grants: $5.4M; 11 awards · 2020–2025; Rank in peer group#137 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Feb 2025Federal grantHealth and Human S · Phase II · A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$979K
Mar 2024Federal grantHealth and Human S · Phase I · Proof of concept studies for in vivo produced CAR-T cells that target B cell follicles as a treatment for HIV$302K
Feb 2024Federal grantHealth and Human S · Phase II · A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$1M
Feb 2023Federal grantHealth and Human S · Phase II · A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$55K
Dec 2022Federal grantHealth and Human S · Phase I · Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells$307K
Nov 2022Federal grantHealth and Human S · Phase II · Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$119K
Aug 2022Federal grantHealth and Human S · Phase II · Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$1M

Show 4 earlier federal awards

Jul 2022Federal grantHealth and Human S · Phase II · A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed$300K
Aug 2021Federal grantHealth and Human S · Phase II · Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$1M
Feb 2021Federal grantHealth and Human S · Phase I · Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$52K
Jun 2020Federal grantHealth and Human S · Phase I · Development of a treatment for the durable remission of HIV using autologous human CAR T cells that target B cell follicles$300K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#137 · top 27%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

EQUATOR THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
EXONANORNA, LLCSimilar federal contract value in Biotech · null in contracts
Gadusol Laboratories, Inc.Similar federal contract value in Biotech · null in contracts
PHUSIS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
EINSENCA INC.Similar federal contract value in Biotech · null in contracts
FURANICA, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.